Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility
Lung Disease
Bottom Line
View on ClinicalTrials.gov: NCT02234128 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Toronto EVLP System™ (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Lung Bioengineering Inc.
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Count of Participants With Primary Graft Dysfunction (PGD), Grade 3 |
8; 8; 2 | — |
| PRIMARY Count of Participants Surviving |
35; 31; 52 | — |
| SECONDARY PGD Score |
8; 8; 2; 8; 7; 3 | — |
| SECONDARY ICU Length of Stay |
17.0; 9.0; 5.0 | — |
| SECONDARY Total Lung Preservation Time (TPT) |
13.4; 12.2; 3.0 | — |
| SECONDARY Time to First Extubation |
78.1; 31.1; 21.5 | — |
| SECONDARY Hospital Length of Stay |
36.0; 19.0; 18.0 | — |
Summary
Eligibility Criteria
Subject Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female patients
- All patients, 18 years of age or older
- Patient already on or added to the active waiting list for a single or bilateral lung transplant
- Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant
- Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant
Subject Exclusion Criteria:
A subject who meets any of the following criteria will be excluded from participation:
- Patients listed for same-side lung re-transplantation
- Patients listed for multiple organ transplantation including lung and any other organ
- Patients listed for live donor lobar transplant
- Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia
- Patients not initially consented into the study prior to the time of lung transplant
- Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS).
Donor Lung Inclusion Criteria for EVLP Assessment:
The donor lung must meet at least one of the following criteria to proceed with EVLP:
- At the time of the clinical evaluation, the donor PaO2/FiO2 6 hours
- Donor age ≥ 55 years old
- Study Center Investigator requires additional assessment ex vivo and/or extended preservation time
Donor Lung Exclusion Criteria for EVLP Assessment:
The donor lung is excluded from EVLP if at least one of the following criteria have been met:
- The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy
- Non-persistent purulent secretions that do not clear by hour 3 on EVLP
- The donor lung has confirmed evidence of aspiration
- The donor lung has significant mechanical lung injury or trauma
- The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility > 10 hours
EVLP Lung Inclusion Criteria for Transplantation:
The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator:
- PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period
- and 1 hour and ≤ 10 hours
- the EVLP time > 3 hours and ≤ 6 hours
- the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 6 hours for the first lung
- the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 10 hours for the second lung
- and Study Center Investigator deems lung function suitable for intended subject
EVLP Lung Exclusion Criteria for Transplantation:
The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met:
- PvO2/FiO2 10 hours
- EVLP 6 hours
- CIT-2 6 hours for first lung or > 10 hours for second lung
- or Study Center investigator deems lung function unsuitable for intended subject
Data sourced from ClinicalTrials.gov (NCT02234128). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.